Papers: 29 Nov 2013 - 6 Dec 2013
[Clinical and electrophysiological and molecular genetic characteristics of the course of relapsing-remitting multiple sclerosis.]
[The CD100 semaphorin expression on peripheral blood T-lymphocytes in patients with relapsing-remitting multiple sclerosis.]
[Relationship between biochemical parameters of cerebrospinal fluid and the course of multiple sclerosis.]
[Prognostic factors of multiple sclerosis in children and adolescents after the first demyelinating event.]
[Differential diagnosis of multiple sclerosis with pediatric onset: the experience of the Moscow Division for treatment of children and adolescents with multiple sclerosis.]
[Clinical epidemiology of multiple sclerosis in Moscow. Discriptive epidemiology in population of one region of Moscow.]
[Quality of life of patients receiving long-term treatment with first-line disease-modifying drugs: results of a Russian multicenter study using MusiQoL.]
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
[Local reactions to disease-modifying drugs: pathogenesis and relationship to clinical effectiveness.]
A Meta-analysis of the relation between chemokine receptor 5 delta32 polymorphism and multiple sclerosis susceptibility.
Neuromyelitis Optica Preceded by HyperCKemia and a Possible Association with Coxsackie Virus Group A10 Infection.
Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
The association of alcohol consumption and smoking with quality of life, disability and disease activity in an international sample of people with multiple sclerosis.
Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment.
The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals.
FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.
Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence.
Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).
Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Does long-term partial sodium channel blockade alter disease progression in MS? Evidence from a retrospective study.
Protocol to isolate a large amount of functional oligodendrocyte precursor cells from the cerebral cortex of adult mice and humans.
Erratum: Genomic analysis of ERVWE2 locus in patients with Multiple sclerosis: absence of genetic association but potential role of Human Endogenous retrovirus type W elements in molecular mimicry with myelin antigen.
Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination.
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Catechol-O-Methyltransferase Val158Met Polymorphism (rs4680) Is Associated With Pain in Multiple Sclerosis.
[Autonomic nervous system alteration in multiple sclerosis patients with urinary symptoms. Clinical, urodynamic and cardiovascular study].
Clinical Outcome of 50 Progressive Multiple Sclerosis Patients Treated with Cellular Therapy in Iraq.
Extremely low-frequency pulsed magnetic fields and multiple sclerosis: effects on neurotransmission alone or also on immunomodulation? Building a working hypothesis.
Behçet's Disease Presenting with Acute Transverse Myelitis: MRI Findings and Review of the Nosology. A Case Report.
Diagnostic problems in "clinically definite" multiple sclerosis patients with normal CSF and multiple MRI abnormalities.
Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases.